Home
News
301
Results found
-
MOMENTUM study launched: Learning from every cancer patient treated with magnetic resonance radiation therapy
On February 4, 2019, the Multiple Outcome Evaluation of Radiotherapy Using the MR-linac (MOMENTUM) study was launched by the international MR-linac Consortium. The study represents the next step in the development of the Elekta Unity MR/RT system, a ground-breaking approach to reduce side effects when treating tumors. -
Seasonal Greetings
On behalf of the entire team at Lygature we want to thank you for the inspiring collaborations that have contributed to our mission to pioneer medicine. We wish you and your loved ones all the best in 2019 and are looking forward to collaborating, learning, challenging the status quo and addressing unmet medical needs wherever patients are in the world. Towards a happy and healthy new year! -
Showcasing the R&D landscape in the Netherlands for foreign investors
-
Join our team as Program Manager- Data Infrastructure
Make the next move towards a challenging and rewarding career by becoming a Program Manager Data Infrastructure at Lygature – the Netherlands’ leading translational research facilitator. -
Partnerships MeetUp 2018: providing a safe space for innovation & implementation
A key factor for successful collaboration in life sciences & health, is a safe space for innovation and implementation. At Lygature, we aim to provide just that. Our 2018 Partnerships MeetUp held on November 1st, 2018 made this even more tangible. -
ADAPT SMART and EU Lead Factory win Best IMI Communication Product Awards
Yesterday, the ADAPT SMART infographic and the European Lead Factory animation won the best Innovative Medicines Initiative (IMI) Communication Product Awards. The awards were handed out as part of IMI’s 10th anniversary during the IMI Scientific Symposium in Brussels. -
Lygature Scientific Advisory Board: “Lygature is all about managing complexity”
-
Register for work meeting for public-private research consortia before May 16
New program under Commit2Data umbrella will exist of 4-6 public private research projects, focusing on development of new approaches of prevention and early detection of cardiovascular disease. -
Will you become our new colleague? Lygature is hiring a Program Manager Data Infrastructure
As we are expanding our project portfolio, we are looking for a Program Manager Data Infrastructure. -
GHIT Fund invests in new partnership for diagnosis of schistosomiasis
The Japanese Global Health Innovative Technology Fund (GHIT) announced today that is investing approximately 76 million yen (US$0.7 million) in a partnership involving Japan’s Institute of Tropical Medicine, Nagasaki University (NEKKEN) and the Netherlands-based Lygature and Leiden University Medical Center (LUMC). -
Will you become our new colleague? Lygature is hiring a Legal & Business Development manager
As we are expanding our project portfolio, we are looking for a Legal & Business Development manager. -
Discover Europe’s most attractive life sciences environment
The Dutch life sciences sector has produced a bidbook to attract foreign investor, companies and researchers. -
Will you become our new colleague? Lygature is hiring
As we are expanding our project portfolio, we will be hiring two entry-level Program Managers. -
Launch of Oncode Institute: outsmarting cancer and impacting lives
Yesterday, H.M. Queen Máxima officially launched Oncode Institute! 43 excellent cancer research groups in the Netherlands will work together in Oncode Institute to bring fundamental insights into a clinical setting to improve patient outcomes. As Lygature, we are proud to work as a partner in Oncode Institute to support excellent research. -
US GAO Report Identifies Challenges for Generic Versions of Nonbiological Complex Drugs
On January 16, 2018, the U.S. Government Accountability Office (GAO) released a report that examines the challenges of reviewing generic versions of nonbiological complex drugs (NBCDs). The report underlines the scientific challenges involved when demonstrating equivalence between brand and generic NBCDs.